论文部分内容阅读
目的探讨对e抗原阳性慢性乙型肝炎患者采用恩替卡韦(ETV)治疗的远期疗效。方法收集恩平市人民医院收治的e抗原阳性慢性乙型肝炎患者120例,将患者分为研究组与对照组各60例,对照组采用干扰素α-2b治疗,研究组在干扰素的基础上给予ETV治疗。结果研究组治疗后1、3、5年HBe Ag阴转率、HBe Ag血清学转换率、血清HBV DNA转阴率、血清ALT复常率均显著高于对照组(P<0.05);研究组治疗后3个月、1年、3年、5年血清HBV DNA定量与Child-Pugh评分显著低于对照组(P<0.05)。结论对e抗原阳性慢性乙型肝炎患者采用ETV治疗,能有效抑制HBV DNA,并提高HBe Ag转阴率及HBe Ag血清学转换率,还能有效改善患者的肝功能。
Objective To investigate the long-term efficacy of entecavir (ETV) for e antigen-positive chronic hepatitis B patients. Methods Enping City People’s Hospital admitted 120 patients with e antigen-positive chronic hepatitis B, the patients were divided into study group and control group of 60 cases, the control group treated with interferon α-2b, the study group on the basis of interferon Give ETV treatment. Results After 1, 3 and 5 years of treatment, the rates of HBeAg negative conversion, HBeAg seroconversion, serum HBV DNA negative conversion and serum ALT abnormalities were significantly higher in the study group than those in the control group (P <0.05) Serum HBV DNA and Child-Pugh scores at 3, 1, 3 and 5 years after treatment were significantly lower than those in the control group (P <0.05). Conclusion ETV treatment of patients with e antigen-positive chronic hepatitis B can effectively inhibit HBV DNA, improve HBe Ag conversion rate and HBeAg seroconversion rate, and can effectively improve the patient’s liver function.